Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

184 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
Guichard S, Hennebelle I, Bugat R, Canal P. Guichard S, et al. Among authors: bugat r. Biochem Pharmacol. 1998 Mar 1;55(5):667-76. doi: 10.1016/s0006-2952(97)00541-8. Biochem Pharmacol. 1998. PMID: 9515577
Mechanism-based models for topotecan-induced neutropenia.
Léger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, Chatelut E. Léger F, et al. Among authors: bugat r. Clin Pharmacol Ther. 2004 Dec;76(6):567-78. doi: 10.1016/j.clpt.2004.08.008. Clin Pharmacol Ther. 2004. PMID: 15592328
Population pharmacokinetics of oxaliplatin.
Delord JP, Umlil A, Guimbaud R, Grégoire N, Lafont T, Canal P, Bugat R, Chatelut E. Delord JP, et al. Among authors: bugat r. Cancer Chemother Pharmacol. 2003 Feb;51(2):127-31. doi: 10.1007/s00280-002-0550-3. Epub 2002 Dec 4. Cancer Chemother Pharmacol. 2003. PMID: 12647013
The effects of food on the pharmacokinetic profile of oral vinorelbine.
Bugat R, Variol P, Roché H, Fumoleau P, Robinet G, Senac I. Bugat R, et al. Cancer Chemother Pharmacol. 2002 Oct;50(4):285-90. doi: 10.1007/s00280-002-0475-x. Epub 2002 Aug 15. Cancer Chemother Pharmacol. 2002. PMID: 12357302 Clinical Trial.
Individual adaptive dosing of topotecan in ovarian cancer.
Montazeri A, Culine S, Laguerre B, Pinguet F, Lokiec F, Albin N, Goupil A, Déporte-Féty R, Bugat R, Canal P, Chatelut E. Montazeri A, et al. Among authors: bugat r. Clin Cancer Res. 2002 Feb;8(2):394-9. Clin Cancer Res. 2002. PMID: 11839654 Clinical Trial.
Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
Arnould S, Guichard S, Hennebelle I, Cassar G, Bugat R, Canal P. Arnould S, et al. Among authors: bugat r. Biochem Pharmacol. 2002 Oct 15;64(8):1215-26. doi: 10.1016/s0006-2952(02)01291-1. Biochem Pharmacol. 2002. PMID: 12234602
In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D, Delord JP, Rochaix P, Mallard V, Thomas F, Hennebelle I, Bugat R, Canal P, Allal C. Balin-Gauthier D, et al. Among authors: bugat r. Cancer Chemother Pharmacol. 2006 Jun;57(6):709-18. doi: 10.1007/s00280-005-0123-3. Epub 2005 Dec 1. Cancer Chemother Pharmacol. 2006. PMID: 16320055
In vitro, cetuximab combined with oxaliplatin significantly decreased the IC50 values of oxaliplatin in HCT-8 (EGF-R moderate) and HT-29 (EGF-R weak) cell lines, while SW620 (EGF-R negative) and HCT-116 (EGFR strong) cell lines remained unresponsive. ...
In vitro, cetuximab combined with oxaliplatin significantly decreased the IC50 values of oxaliplatin in HCT-8 (EGF-R moderate) and HT …
Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation.
Delord JP, Léger F, Canal P, Poublanc M, Bugat R, Chatelut E. Delord JP, et al. Among authors: bugat r. Cancer Chemother Pharmacol. 2006 Aug;58(2):189-94. doi: 10.1007/s00280-005-0142-0. Epub 2005 Nov 22. Cancer Chemother Pharmacol. 2006. PMID: 16328415 Clinical Trial.
Vinorelbine-related cardiac events: a meta-analysis of randomized clinical trials.
Lapeyre-Mestre M, Gregoire N, Bugat R, Montastruc JL. Lapeyre-Mestre M, et al. Among authors: bugat r. Fundam Clin Pharmacol. 2004 Feb;18(1):97-105. doi: 10.1046/j.0767-3981.2003.00215.x. Fundam Clin Pharmacol. 2004. PMID: 14748761
Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design.
Khayat D, Rixe O, Brunet R, Goupil A, Bugat R, Harousseau JL, Ifrah N, Puozzo C. Khayat D, et al. Among authors: bugat r. Cancer Chemother Pharmacol. 2004 Sep;54(3):193-205. doi: 10.1007/s00280-004-0794-1. Epub 2004 May 25. Cancer Chemother Pharmacol. 2004. PMID: 15160284 Clinical Trial.
184 results
Jump to page
Feedback